Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00781846
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ridaforolimus — DRUG
    oral tablets, daily for 5 days/week
  • bevacizumab — DRUG
    IV infusion

Study Details

The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced cancers.

Key Dates

First listed
Oct 29, 2008
Start date
Oct 31, 2008
Status verified
Feb 2015
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010

Study Design

Enrollment
17 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
  • Experimental: 2
    40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
  • Experimental: 3
    40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks

Primary Outcome Measure

Identification of recommended phase 2 dose of ridaforolimus in combination with bevacizumab [ Time Frame: Duration of the trial ]

Related Studies